Seattle: Microsoft Corp came out on top in the first of two patent trials versus Google Inc's Motorola Mobility unit , as a federal judge in Seattle ruled largely in its favour.
US District Judge James Robart in Seattle said Microsoft owed only a fraction of the royalties Motorola had claimed for use of its technology in Microsoft's Xbox console.
Motorola had sought as much as $4 billion a year for use of its so-called standard, essential wireless and video patents, while Microsoft argued its rival deserved about $1 million a year. Robart decided the appropriate payment was about $1.8 million.
Microsoft welcomed the outcome....
more
11:09 AM, Apr 27, 2013
Washington: Apple Inc scored a win on Monday when the US International Trade Commission ruled that it did not violate a Google patent to make the popular iPhones. Apple had initially been accused of infringing on six patents for iPhone-related technology covering everything from reducing signal noise to programming the device's touchscreen so a user's head does not accidentally activate it while talking on the phone. If Apple had been...
10:06 AM, Apr 23, 2013
Washington: DNA may be the building block of life, but can something taken from it also be the building block of a multimillion-dollar medical monopoly? The US Supreme Court grapples with the question of whether human genes can be patented. Its ultimate answer could reshape US medical research, the fight against diseases like breast and ovarian cancer and the multi-billion dollar medical and biotechnology business. "The intellectual framework that comes...
02:30 PM, Apr 15, 2013
Washington: Samsung Electronics Co Ltd infringed a key portion of an Apple Inc patent by including a text-selection feature in its smartphones and tablets, an International Trade Commission judge said in a preliminary decision. South Korean-based Samsung did not infringe portions of a second Apple patent that allows a device to detect if a microphone or other device is plugged into its microphone jack, the judge said in a decision...
04:08 AM, Apr 07, 2013
New Delhi: The Delhi High Court on Friday refused to grant interim relief on a patent row to US pharmaceuticals major Merck Sharp and Dohme (MSD) which sought a restraint on Indian firm Glenmark Pharmaceuticals manufacturing and marketing anti-diabetes drugs Zita and Zita-Met. Justice Rajiv Sahai Endlaw dismissed the interim application of the multinational pharma major the Mumbai-based firm be restrained from manufacturing and selling the anti-diabetes medicines on the...
05:54 PM, Apr 05, 2013
Prathiba M Singh, advocate for Ranbaxy and Cipla, fought the Glivec patent case against Novartis. She joined IBNLive readers for an interaction on the legal and moral compulsions behind this courtroom battle and the significance of the Supreme Court's decision for Indian pharma firms and the people of the country. ...
06:33 PM, Apr 03, 2013
The US industry on Wednesday said it is reviewing the order of the Supreme Court early this week that denied patent on Glivec, a cancer medication produced by Swiss drug maker Novartis, as Corporate America expressed dismay at the court verdict. ...
01:00 PM, Apr 03, 2013
Expressing unease over the Supreme Court ruling against pharmaceutical giant Novartis denying the company a patent on its cancer drug, a major business advocacy group on Tuesday said that this would impact innovation and investment climate in India at a time when the country needs foreign direct investment the most. ...
10:43 AM, Apr 03, 2013
In a landmark verdict, the Supreme Court of India dismissed a plea by the Swiss pharmaceutical giant Novartis on Monday for a patent on its cancer drug Glivec, paving way for more affordable life saving drug. ...
11:31 PM, Apr 02, 2013
The secretary general of the Indian Pharmaceutical Alliance, DG Shah said that Novartis was merely posturing and it could not ignore the huge market that India provided to its products. ...
09:15 PM, Apr 01, 2013
The Supreme Court on Monday dismissed Swiss drugmaker Novartis's attempt to win patent protection for its cancer drug Glivec. ...
07:52 PM, Apr 01, 2013
In a landmark verdict, the Supreme Court dismissed a plea by the Swiss pharmaceutical giant Novartis on Monday for a patent on its cancer drug Glivec, paving the way for more affordable life-saving cancer drugs. How does it affect the Indian pharmaceutical industry and the global biggies who are looking at India as a quick-growth market? Pharmaceutical industry expert Vikas Dandekar joined IBNLive readers for an interaction on the issue....
05:30 PM, Apr 01, 2013
After the Supreme Court dismissed Swiss pharma company Novartis' plea for a patent on its drug Glivec, pharma expert vikas Dandekar said, "This will be a far reaching decision. Innovation on one side, access and affordability on the other side. The balance has to be done". ...
03:37 PM, Apr 01, 2013
Pharmaceutical giant Novartis on Monday termed the Supreme Court's judgement of not granting a patent to its cancer drug Glivec as "disappointing" and warned that though it will continue to introduce new products in India, it will now invest "cautiously". In a landmark verdict, the apex court dismissed the Swiss company's plea, paving way for more affordable life saving cancer drugs. ...
03:28 PM, Apr 01, 2013
In a landmark verdict, the Supreme Court of India dismissed a plea by the Swiss pharmaceutical giant Novartis on Monday for a patent on its cancer drug Glivec, paving way for more affordable life saving cancer drugs. "Generic companies will have a levy that will allow them to survive in India for a considerable period of time," said Anand Grover, lawyer, Cancer Patients Aid Association. ...
02:14 PM, Apr 01, 2013
Swiss pharmaceutical company Novartis, which lost its battle for patent on its cancer drug Glivec in India on Monday, said the Supreme Court's ruling discourages innovative drug discovery and is a setback for patients. ...
01:38 PM, Apr 01, 2013
Shares of the Swiss pharmaceutical giant Novartis fell about 4.5 per cent on Monday after the Supreme Court of India dismissed its plea for a patent on its cancer drug, Gelvic. Shares of select Indian pharmaceutical companies rallied as the industry is set to receive a boost following the verdict. ...
11:48 AM, Apr 01, 2013
The Supreme Court dismissed a plea by the Swiss pharmaceutical giant Novartis on Monday for a patent on its cancer drug Glivec, paving way for more affordable life saving cancer drugs. Novartis had sought to overturn a clause in Indian Patents Law that restricts patent protection for newer forms of existing molecules, and the ruling could set a precedent for how other similar patent claims are treated. ...
11:25 AM, Apr 01, 2013
In a landmark verdict, the Supreme Court of India dismissed a plea by the Swiss pharmaceutical giant Novartis on Monday for a patent on its cancer drug Glivec, paving way for more affordable life saving drug. Novartis had sought to overturn a clause in Indian Patents Law that restricts patent protection for newer forms of existing molecules, and the ruling could set a precedent for how other similar patent claims...
11:05 AM, Apr 01, 2013
The Supreme Court on Monday is likely to pronounce its verdict in the much awaited patent case involving Glivec - the anti-cancer drug manufactured by Swiss pharma-giant Novartis - priced at a whopping Rs 1.2 lakhs for a monthly dosage. The case dates back to India's denial of a patent in 2006 on the grounds that it wasn't considered a new molecule, but an altered version of one that had...
08:37 AM, Apr 01, 2013
